Premium Nahrungsergänzungsmittel | artgerecht

Ixekizumab: Uses, Mechanism & Side Effects

Ixekizumab is a monoclonal antibody used to treat plaque psoriasis, psoriatic arthritis, and spondyloarthritis by selectively blocking interleukin-17A.

Regular tips about health Regular tips about health

Things worth knowing about "Ixekizumab"

Ixekizumab is a monoclonal antibody used to treat plaque psoriasis, psoriatic arthritis, and spondyloarthritis by selectively blocking interleukin-17A.

What is Ixekizumab?

Ixekizumab is a biotechnologically produced, humanized monoclonal antibody belonging to the class of biologics. It is marketed under the brand name Taltz® and targets the cytokine interleukin-17A (IL-17A), a key signaling protein of the immune system involved in inflammatory processes. The medication is administered by subcutaneous injection (under the skin) and is approved for adults as well as, in certain cases, children and adolescents.

Indications

Ixekizumab has been approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for the following conditions:

Moderate-to-severe plaque psoriasis in adults and children aged 6 years and older
Psoriatic arthritis in adults, alone or in combination with methotrexate
Ankylosing spondylitis (radiographic axial spondyloarthritis) in adults
Non-radiographic axial spondyloarthritis in adults with objective signs of active inflammation

Mechanism of Action

Ixekizumab binds with high specificity to interleukin-17A (IL-17A), a pro-inflammatory cytokine produced by T helper cells (Th17 cells). IL-17A plays a central role in promoting inflammation and the excessive immune response observed in conditions such as psoriasis and spondyloarthritis. By blocking IL-17A, ixekizumab prevents this signaling molecule from binding to its receptor, thereby interrupting the inflammatory cascade. This leads to a significant reduction in skin inflammation, joint symptoms, and other disease manifestations.

Dosage and Administration

Ixekizumab is administered as a subcutaneous injection using a pre-filled autoinjector pen or pre-filled syringe. The dosing schedule varies by indication:

Plaque psoriasis (adults): 160 mg as a starting dose (two 80 mg injections), followed by 80 mg every 2 weeks up to week 12, then 80 mg once monthly
Psoriatic arthritis and spondyloarthritis: 160 mg starting dose, followed by 80 mg once monthly
Children (psoriasis): Dose is determined by the child's body weight

The injection can be administered by a healthcare professional or, after appropriate training, by the patient at home.

Side Effects

Like all biologics, ixekizumab may cause side effects. Common side effects include:

Injection site reactions (redness, pain, swelling)
Upper respiratory tract infections (e.g., common cold, sinusitis)
Nausea
Fungal infections (e.g., oral candidiasis)

Less common but more serious side effects include:

Serious infections (e.g., reactivation of tuberculosis)
Neutropenia (reduction in certain white blood cells)
Inflammatory bowel disease (particularly Crohn's disease)
Severe allergic reactions (hypersensitivity)

Contraindications and Precautions

Ixekizumab must not be used in patients with:

Known hypersensitivity to the active substance or any excipients
Clinically important active infections

Prior to initiating treatment, patients should be screened for tuberculosis. Patients should be monitored for signs of infection throughout therapy. Special caution is required in patients with a history of inflammatory bowel disease.

Treatment Context and Clinical Outcomes

Ixekizumab is generally prescribed when conventional therapies (e.g., methotrexate, ciclosporin, phototherapy) have proven insufficient or are not tolerated. In clinical trials, ixekizumab demonstrated clear superiority over placebo and conventional treatments. A significant proportion of patients achieved complete or near-complete skin clearance (PASI 90 or PASI 100). Treatment is regularly monitored by a physician to assess efficacy and safety.

References

European Medicines Agency (EMA): Taltz (ixekizumab) - Product Information. Available at: www.ema.europa.eu
Griffiths CEM et al. - Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. The Lancet. 2015;386(9993):541-551.
Prescribing Information Taltz® 80 mg solution for injection, Eli Lilly and Company, current version as per regulatory approval.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.